Viatris Stock News

Viatris Inc (NASDAQ: VTRS ) is trading lower Monday after the company reported worse-than-expected top-line results for the fourth quarter and issued guidance below estimates. Viatris reported quarterly revenue of $4.33 billion, which came in below the $4.35 billion estimate. The company said it expects full-year 2022 revenue to be between $17 billion and $17.5 billion versus the $17.6 billion estimate. Viatris'' board authorized a share repurchase program of up to $1 billion. "The board of directors has worked closely and strategically … Full story available on Benzinga.com

Biocon Biologics (BBL) will get the global biosimilar business of Viatris in developed and emerging markets, with an estimated revenue of $875 million and an operating profit of $200 million for 2022. Biocon Biologics has estimated $1.1 billion in revenue and $250 million in earnings before interest, tax, depreciation and amortisation from the business in 2023, she said. "Going forward it is going to be much higher," said Mazumdar-Shaw.

Biocon Biologics estimates it will gain access to Viatris’ global biosimilars business that is expected to hit $1 bn in revenue next year

Viatris, Inc. (VTRS) CEO Michael Goettler on Q4 2021 Results - Earnings Call Transcript

Viatris (VTRS) has lost more than a fifth to reach a 52-week low on Monday as Wall Street reacts to the generic drugmaker’s lower than expected guidance and its…

NEW YORK , Feb. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, CEI, PLTR, AAL, and VTRS. … Full story available on Benzinga.com

Viatris stock tumbled Monday on its plan to sell its biosimilars portfolio to Biocon Biologics. The deal is set to close later this year.

U.S. health care company Viatris, formerly known as Myland, on Monday announced it had agreed to pay $264 million to settle a class-action lawsuit over the pricing of EpiPens.The agreement, which must still be approved by the court, would seek…

Shares of biotechnology major Biocon on Monday tanked over 11 per cent after the company said its subsidiary Biocon Biologics has inked a pact to acquire Viatris Inc''s biosimilars business. Get more Companies News and Business News on Zee Business.

Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its busi

Viatris reported Q4-2021 results and gave mediocre guidance for 2022.

Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has agreed to pay $264 million to resolve a class-action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen al

Earnings that missed expectations and a soft outlook for 2022 disappointed investors.